全文获取类型
收费全文 | 25793篇 |
免费 | 2652篇 |
国内免费 | 520篇 |
专业分类
耳鼻咽喉 | 135篇 |
儿科学 | 1030篇 |
妇产科学 | 785篇 |
基础医学 | 613篇 |
口腔科学 | 175篇 |
临床医学 | 1906篇 |
内科学 | 2275篇 |
皮肤病学 | 141篇 |
神经病学 | 191篇 |
特种医学 | 492篇 |
外国民族医学 | 64篇 |
外科学 | 2453篇 |
综合类 | 3186篇 |
现状与发展 | 2篇 |
预防医学 | 541篇 |
眼科学 | 100篇 |
药学 | 2156篇 |
17篇 | |
中国医学 | 801篇 |
肿瘤学 | 11902篇 |
出版年
2024年 | 57篇 |
2023年 | 315篇 |
2022年 | 731篇 |
2021年 | 1006篇 |
2020年 | 885篇 |
2019年 | 807篇 |
2018年 | 811篇 |
2017年 | 922篇 |
2016年 | 1154篇 |
2015年 | 1071篇 |
2014年 | 1572篇 |
2013年 | 2090篇 |
2012年 | 1440篇 |
2011年 | 1656篇 |
2010年 | 1257篇 |
2009年 | 1281篇 |
2008年 | 1256篇 |
2007年 | 1408篇 |
2006年 | 1276篇 |
2005年 | 1075篇 |
2004年 | 863篇 |
2003年 | 782篇 |
2002年 | 690篇 |
2001年 | 627篇 |
2000年 | 516篇 |
1999年 | 492篇 |
1998年 | 388篇 |
1997年 | 395篇 |
1996年 | 283篇 |
1995年 | 263篇 |
1994年 | 252篇 |
1993年 | 167篇 |
1992年 | 138篇 |
1991年 | 135篇 |
1990年 | 109篇 |
1989年 | 100篇 |
1988年 | 86篇 |
1987年 | 76篇 |
1986年 | 62篇 |
1985年 | 78篇 |
1984年 | 70篇 |
1983年 | 60篇 |
1982年 | 41篇 |
1981年 | 45篇 |
1980年 | 41篇 |
1979年 | 34篇 |
1978年 | 34篇 |
1977年 | 26篇 |
1976年 | 27篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
观察雾化吸入IL-2联合化疗对非小细胞肺癌的临床疗效并与静滴IL-2及单纯化疗进行对比。方法:IL-2的雾化10万u/次,2次/d,连用1月,化疗后3d开始用;IL-2静滴40万u/次,1次/d,加入500ml液体中静滴,连用1月;化疗采用动脉灌注或全身化疗,药物及剂量为环磷酰胺400mg/m2+DDP80mg/m2。结果:用IL-2的两组CR+PR显著高于单纯化疗组(P<0.01);雾化IL-2组CR+PR与静滴IL-2差别无显著性(P>0.05),但不良反应的发生率显著低于后者,而与单纯化疗类似,结论:雾化吸入IL-2联合化疗对非小细胞肺癌有较好的疗效,且副作用小,值得扩大样本进一步验证其疗效。 相似文献
62.
63.
Anders Wahlin Lorentz Brinch Per Hrnsten Stein A. Evensen Gunnar
berg Bengt Simonsson Michael Hedenus 《European journal of haematology》1997,58(4):233-240
Abstract: The results of an intensive treatment program for patients 16–60 yr of age with de novo acute myeloid leukemia are presented. The patients were given conventional induction treatment with daunorubicin and cytarabine. Patients not entering complete remission (CR) after 1 course of daunorubicin/cytarabine were given 1 course of amsacrine/etoposide/cytarabine. Those entering complete remission received 3 consolidation courses using mitoxantrone, etoposide, amsacrine and cytarabine. One hundred and eighteen patients were enrolled. Complete remission was attained after 1–2 courses in 90 patients (76%). Another 6 patients reached CR after 3–4 induction courses for a total CR rate of 81%. If feasible, patients were offered either allogeneic or unpurged autologous bone marrow transplantation. Twenty-four patients underwent allogeneic bone marrow transplantation; 15 in first remission, 8 in second remission, 1 in early relapse. Thirty patients below 56 yr of age underwent autologous bone marrow transplantation in first remission. The overall probability of survival at 4 yr was 34%, and for patients below 40 yr of age 50%. Leukemia-free survival was 35% for the whole cohort of patients; 52% for patients below 40 yr of age. Patients undergoing allogeneic or autologous bone marrow transplantation in first remission had an overall survival of 86% and 47%, respectively, while the probability of leukemia-free survival in these groups was 87% vs. 40% at 4 yr. The CR rate and long-term results of this intensive treatment program compare favorably with other recent studies using intensive consolidation with allogeneic or autologous bone marrow transplantation or high dose cytarabine. 相似文献
64.
Jin S. Lee Herman I. Libshitz William K. Murphy Diane Jeffries Waun K. Hong 《Investigational new drugs》1990,8(3):299-304
Summary Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m2, with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33–75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12–65+). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34–88 mg/m2of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC. 相似文献
65.
Acute myeloid leukaemia (AML) is predominantly a disease of the elderly; the median age of incidence is 64 years, and 60% of all cases are over 60. With improved chemotherapy regimens and maximal supportive care, remission rates of up to 60% may be achieved in selected elderly patients. Whilst intensive chemotherapy is the treatment of choice for fit patients, it may be inappropriate for debilitated patients with poor prognosis disease in whom supportive care or palliative chemotherapy may be more suitable. AML in the elderly exhibits biological differences from AML in younger patients, and elderly patients may be unable to withstand the rigors of the intensive treatment regimens given to younger patients. 相似文献
66.
67.
Doug Joshua Max Wolf Jane Matthews Lee Tan William Sheridan Glenn Pilkingtonh Fiona Page 《Leukemia & lymphoma》1994,14(3):303-309
The Australian Leukaemia Study Group myeloma study (MM1) aimed to determine the prognostic significance of clinical and immunophenotypic markers in patients with multiple myeloma. All patients were treated with standard dose melphalan and prednisone. Seventy-four patients were entered and the median survival was 27 months. Serum beta 2-microglobulin (βM) and albumin levels were the only significant clinical factors influencing survival (p = 0.007 and p = 0.008, respectively). Patients with raised levels of CD38+ lymphocytes at presentation had a significantly shorter survival than patients with normal levels (p = 0.01, logrank test, median 19 months vs 33 months). CD38 antigen expression was independent of β2M but patients with raised levels of CD38 had significantly lower levels of albumin than patients with normal levels (p = 0.001) which may explain their poorer survival. Salmon and Durie stage was not associated with antigen expression. No other B-cell antigens (CD10, CD19, CD20, CD21, CD22, CD23, FMC1 or FMC7) or plasma cell antigens tested (PCA-1) were found to be associated with prognosis. Patients who achieved plateau phase had a better prognosis than those who did not (p = 0.04 in a landmark analysis). Patients who achieved plateau phase following an objective response appeared to have a better prognosis than those who were in plateau phase at presentation (p = 0.09 in a landmark analysis). Light chain isotype suppression (LCIS) was not associated with a significant survival advantage and did not correlate with any known prognostic indicator. We conclude that phenotypic analysis of peripheral blood lymphocytes for CD38 antigen at diagnosis may be useful as a prognostic indicator in patients with myeloma. 相似文献
68.
光动力学疗法与局部化疗联合治疗进展期食管贲门癌 总被引:2,自引:0,他引:2
作应用光动力学疗法(PDT)对进展期食管贲门癌55例进行治疗,并对其中15例联合应用内镜下局部注射抗癌药物。对每一患均先静脉滴注血卟啉衍生物(HPD)5mg/kg,于用药后24,48和72h分别用波长630nm的铜蒸汽激光照射肿瘤部位。联合治疗组除PDT治疗外,于每次光照前肿瘤局部注射5-Fu250~500mg。结果:联合治疗组的近期显效率高于单纯PDT组(P〈0.05)。病例随访6~16月, 相似文献
69.
78例胃窦癌的治疗分析 总被引:1,自引:0,他引:1
自1988年2月至1992年8月期间手术治疗的78例胃窦癌患者进行了回顾性分析,手术后肿瘤复发的情况,与十二指肠断端有无癌细胞残存密切相关,并发现于幽门环下切断十二指肠少于3cm者有癌细胞残存达34%,切除十二指肠达3cm者,无论肿瘤分化程度如何,恶性程度高低,切除断端均无癌细胞残存,手术后辅以化疗,对于病人的预后有一定提高。本组随访到的59例病人中,接受化疗的33例,在2年3个月至6年1个月内死亡7例(21.2%),未接受化疗的26例,在5个月至3年8个月内死亡的26例,在5个月至3年8个月内死亡9例(35%)。 相似文献
70.
A. Parthasarathy N. Sumathi R. Manoharan C. D. Natarajan R. Narmada B. R. Santhanakrishnan 《Indian journal of pediatrics》1987,54(5):779-784
Tuberculous infection among children continues to be a significant cause of morbidity. The symptom complex are so variable
among children that the final diagnosis often rests on the laboratory tests. Proper interpretation of the tests, specially
tuberculin test and radiographic studies, are necessary for establishing correct diagnosis. The usefulness of tuberculin test
in both unimmunized and BCG vaccinated children is highlighted. BCG accelerated response as a test should be reserved for
identifying serious form of pulmonary disease or CNS tuberculosis when the tuberculin test is negative. Radiographic assessment
may be sensitive in some instances but not always specific and hence needs cautious interpretation. Tuberculosis among BCG
vaccinated children though not uncommon, needs proper documentation. Current trends in the management of tuberculosis including
CNS forms are briefly outlined. 相似文献